Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBIT: 2009-2024

Historic EBIT for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to -$11.5 million.

  • Heron Therapeutics' EBIT rose 8.19% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 106.16%. This contributed to the annual value of -$11.5 million for FY2024, which is 89.58% up from last year.
  • As of FY2024, Heron Therapeutics' EBIT stood at -$11.5 million, which was up 89.58% from -$110.6 million recorded in FY2023.
  • Heron Therapeutics' EBIT's 5-year high stood at -$11.5 million during FY2024, with a 5-year trough of -$228.2 million in FY2020.
  • For the 3-year period, Heron Therapeutics' EBIT averaged around -$98.9 million, with its median value being -$110.6 million (2023).
  • Its EBIT has fluctuated over the past 5 years, first dropped by 8.29% in 2020, then spiked by 89.58% in 2024.
  • Heron Therapeutics' EBIT (Yearly) stood at -$228.2 million in 2020, then increased by 4.53% to -$217.8 million in 2021, then increased by 19.82% to -$174.7 million in 2022, then surged by 36.67% to -$110.6 million in 2023, then surged by 89.58% to -$11.5 million in 2024.